Novartis Expands Radioligand Production with New Texas Facility

Novartis is set to enhance its US presence by establishing its first Texas manufacturing facility dedicated to cancer therapies. This $23 billion investment over the next five years, including the new 46,000ft² plant in Denton, highlights the pharmaceutical giant’s commitment to expanding its radioligand therapy capabilities in the United States. The move promises to bring significant job opportunities in bioengineering and operations.

As part of its ambitious expansion plan, Novartis is not only building a new site in Texas but also expanding three existing US facilities in New Jersey, Indiana, and California. This strategy underscores the growing demand for next-generation radioligand therapies such as Pluvicto and Lutathera, both approved for use in the US. With ongoing clinical trials targeting various cancers, Novartis is well-positioned to meet future demands. The Denton facility, expected to be fully operational by 2028, will play a crucial role in ensuring a reliable supply chain for these innovative treatments.

Novartis’ strategic investment in Texas marks a significant milestone in its US expansion efforts. By enhancing manufacturing capabilities and addressing the increasing demand for advanced cancer treatments, Novartis not only reinforces its industry leadership but also contributes to local job creation and economic development. As these facilities come online, Novartis will be better equipped to deliver cutting-edge therapies to patients swiftly and effectively.